戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  from premenopause or early perimenopause to postmenopause).
2 lesterol also peaked in late peri- and early postmenopause.
3 ) with perimenopause and 3.5 (1.4, 8.8) with postmenopause.
4 weight gain in women during perimenopause to postmenopause.
5 weight from premenopause to perimenopause to postmenopause.
6  symptoms during the menopause transition or postmenopause.
7 tal CMRglc, the latter being more pronounced postmenopause.
8  brain systems at premenopause compared with postmenopause.
9  hormone-regulated metastasis, both pre- and postmenopause.
10 tumors," such as high body mass index during postmenopause and increased height, are actually signifi
11      SHBG decreased slightly until ~ 4 years postmenopause and increased thereafter.
12 5) among women who transitioned from pre- to postmenopause, and 18.7% (interquartile range, 22.2%; n
13 s [early postmenopause] or >/=10 years [late postmenopause]) and were randomly assigned to receive ei
14 e in LDL cholesterol during perimenopause to postmenopause but could not completely eliminate the ris
15 ccelerated fibrosis was also observed during postmenopause compared with premenopause, for FIB-4 (0.1
16  supplements, and negatively associated with postmenopause, current smoking, and body mass index.
17  each woman as she transitioned from pre- to postmenopause, defined by a biomarker of ovarian functio
18  172 females participating in the Dry Eye in Postmenopause (DEiM) study who had previously been diagn
19  were more likely than those unexposed to be postmenopause (hazard ratio = 1.21, 95% confidence inter
20 ) is evident in hypoestrogenic states (e.g., postmenopause) in which many of these functions go awry.
21 cessfully replicates human perimenopause and postmenopause, including estrous acyclicity and fluctuat
22 ts prior to letrozole treatment and age- and postmenopause-matched healthy women (P = 0.468).
23 ) with perimenopause and 2.6 (1.4, 4.8) with postmenopause; odds ratios for 15 or more apnea and hypo
24 ing to time since menopause (<6 years [early postmenopause] or >/=10 years [late postmenopause]) and
25 95% CI: 0.31, 0.81) in premenopause or <=5 y postmenopause (P-interaction = 0.04).
26 2, 2-12, and >12 months for pre-, peri-, and postmenopause, respectively).
27 h LH and FSH increased until ~ 5 and 7 years postmenopause, respectively, after which they declined,
28  observed in the premenopausal period in the postmenopause (RR of 1.09 (95% CI 0.98-1.21)).
29 t fMRI study to examine how premenopause and postmenopause status affect the neural correlates of epi
30 gression differed between the early and late postmenopause strata (P=0.007 for the interaction).
31 iac CT measures of atherosclerosis in either postmenopause stratum.
32 cebo group and the estradiol group in either postmenopause stratum.
33  long-term effects of mHT initiated in early postmenopause, the observational KEEPS Continuation Stud
34 stmenopausal status, and advanced age within postmenopause, was associated with lower spatial context
35 rotein(a) peaked during late peri- and early postmenopause, while changes in the early stages of meno
36 dy inception (who have since transitioned to postmenopause) who did not have type 2 diabetes before t
37 ociation of premenopause, perimenopause, and postmenopause with sleep-disordered breathing was invest
38  to transdermal estradiol (tE2) during early postmenopause would show cognitive benefits, while oral